entertainment -WSS

entertainment

author：explore 2025-09-27 16:50:13 - browse：3

Moderna's mResvia vaccine — The FDA has approved Moderna’s RSV vaccine for older adults. Moderna

The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.

The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product, its Covid-19 vaccine Spikevax.

“The FDA approval of our second product, mResvia, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stéphane Bancel said in a statement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Eli Lilly’s Mounjaro succeeds in second weight

WSS

Roche subsidiary Foundation Medicine opens new headquarters

Senate panel passes drug pricing bills, but drops one PBM reform

The Readout: Lenmeldy, GLP

Scientists boost immune system in aging mice by making it youthful

There's no autism epidemic. It's an autism diagnosis epidemic

There's no autism epidemic. It's an autism diagnosis epidemic

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Xenotransplantation trials will require adjusting expectations, experts say

Guidelines to prevent youth baseball injuries need more muscle

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Medical records are filled with copy

The thinking behind the controversial eating disorder chatbot Tessa

Guidelines to prevent youth baseball injuries need more muscle

States should stop sabotaging methadone treatment reform

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Steward Health Care has deal to sell doctor network to UnitedHealth

entertainment

The thinking behind the controversial eating disorder chatbot Tessa

Living organ donors deserve priority status for transplants

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Senate panel passes drug pricing bills, but drops one PBM reform

Inside the rise of 'mukbang' eating videos

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

explore

entertainment

hotspot

leisure time